pharma · Prurigo Nodularis · Uremic Pruritus · TRVI
Trevi Therapeutics
Trevi Therapeutics is a pharma organization headquartered in New Haven, USA. It trades on NYSE under ticker TRVI. Primary therapeutic focus areas include Prurigo Nodularis, Uremic Pruritus, Idiopathic Pulmonary Fibrosis
195 Church Street, 16th Floor, New Haven, CT 06510, US HQ
2011 Founded
45 Employees
Public company Type
TRVI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 195 Church Street, 16th Floor, New Haven, CT 06510, US
- Founded
- 2011
- Employees
- 45
- Programs
- 11
- Drugs
- 8
- Patents
- 7
nalbuphine HCl ER
Phase 3 · small molecule · Prurigo Nodularis
nalbuphine HCl ER for Prurigo Nodularis is a Phase 3 program (small_molecule) at Trevi Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TR03ext
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Trevi Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Prurigo Nodularis
- Status
- completed
- Trials
- 1